Amplitude-integrated EEG (aEEG) is a commonly used predictor of outcome after hypoxic ischemic encephalopathy. Cerebral and systemic near-infrared spectroscopy and acute kidney injury might also have prognostic value. The authors monitored neonates with aEEG, cerebral and systemic near-infrared spectroscopy during therapeutic hypothermia, assigned an acute kidney injury stage, and measured neurodevelopmental outcome. For 18 infants, cerebral near-infrared spectroscopy variables did not differentiate between those with favorable (n ¼ 13) versus adverse (death or moderate-severe disability; n ¼ 5) 18-month outcomes. However, systemic rSO 2 variability was higher during hours 48-72 of cooling among those with favorable outcomes (.02 < P < .03). Mean aEEG amplitude during hours 24 to 48 of cooling was higher among those with good outcomes (.027 < P < .032). The aEEG lower margin was also higher during hours 12 to 48 for those with good outcomes (.014 < P < .035). Acute kidney injury did not predict outcome (P > .05). aEEG is a useful prognostic tool for outcomes after neonatal hypoxic ischemic encephalopathy, but the role of near-infrared spectroscopy in the hypothermia-treated population remains uncertain.
Therapeutic hypothermia is now the standard of care for term or near-term neonates with hypoxic ischemic encephalopathy. Despite the most advanced neonatal intensive care, including hypothermia, up to 40% of neonates with hypoxic ischemic encephalopathy have adverse 18-month neurodevelopmental outcomes, [1] [2] [3] and their deficits persist into school age. [4] [5] [6] [7] There remains a pressing need for optimal risk stratification of these infants to effectively test novel therapeutic strategies.
The prognostic utility of amplitude-integrated EEG (aEEG) in the first few hours of life for neonates with hypoxic ischemic encephalopathy is well established, [8] [9] [10] but is altered by therapeutic hypothermia. [11] [12] [13] [14] Interrater reliability for subjective aEEG background interpretation is not perfect, 15 and few have evaluated quantitative measures of the aEEG signal for neonates with hypoxic ischemic encephalopathy.
Changes in cerebral oxygen metabolism have been proposed as potential biomarkers for brain injury in neonatal hypoxic ischemic encephalopathy. The rSO 2 measured by cerebral near-infrared spectroscopy reflects cerebral blood flow and brain oxygen metabolism and might provide prognostic data for 18-month outcomes after hypoxic ischemic encephalopathy. 16, 17 near-infrared spectroscopy recordings can also be employed to measure renal, 18 splanchnic, 19 and peripheral tissue 20 perfusion in critically ill infants.
The authors' previous work suggested that systemic nearinfrared spectroscopy provided better short-term prognostic value than cerebral near-infrared spectroscopy data in neonates with hypoxic ischemic encephalopathy. 21 In addition, emerging evidence suggests that markers of systemic illness are closely associated with short-term neurological outcomes after therapeutic hypothermia for hypoxic ischemic encephalopathy. 22, 23 For example, acute kidney injury is a major risk factor for brain MRI abnormalities after neonatal hypoxic ischemic encephalopathy. 22 The authors hypothesized that markers of systemic illness, such as abnormal systemic perfusion, recorded by nearinfrared spectroscopy, and the presence of renal or hepatic dysfunction may augment the prognostic value of measures of cerebral dysfunction (eg, aEEG and cerebral near-infrared spectroscopy) in first days of life for neonates with hypoxic ischemic encephalopathy. The authors' aim, therefore, was to identify systemic and cerebral risk factors for adverse (or favorable) long-term neurodevelopmental outcomes after neonatal hypoxic ischemic encephalopathy.
Methods
All term neonates admitted to the University of Michigan neonatal intensive care unit whose parents consented to whole-body hypothermia for hypoxic ischemic encephalopathy treatment between January 2009 and February 2011 were enrolled in this study, after written informed consent was provided by the parent. This study was approved by the authors' Institutional Review Board. Details of this cohort's short-term outcomes were analyzed and published previously. 21 
Clinical Care
All infants were cooled according to a published protocol, using a servo-controlled cooling blanket, to 33.5 C + 0.5 C for 72 hours, and were rewarmed using the blanket at 0.5 C per hour until they reached normal body temperature. 2 Demographic information and clinically indicated laboratory testing results (eg, renal and hepatic function tests) were recorded. Pulse oximetry was monitored for each infant, and values were recorded every 5 seconds in a research computer. Blood pressure was measured as clinically required, and values were recorded in a research computer (frequency ranged from every 5 seconds for those who required arterial lines to every 4 hours for those who were hemodynamically stable at the end of the therapeutic hypothermia protocol).
Measures of Systemic Illness
A neonatal modification of the Kidney Disease: Improving Global Outcomes guidelines was used to classify acute kidney injury in the first week of life based on an absolute rise in serum creatinine from a previous trough: Stage 1 ¼ rise of serum creatinine 0.3 mg/dL or serum creatinine 150 to <200%, Stage 2 ¼ rise of serum creatinine 200 to <300%, and Stage 3 ¼ rise of serum creatinine ! 300%, absolute serum creatinine ! 2.5 mg/dL or dialysis. 24 This classification has been used previously for neonates with hypoxic ischemic encephalopathy treated with therapeutic hypothermia. 22, 23 Liver function was classified as definitely abnormal in infants with liver enzyme levels !300% of normal during each 24-hour interval for the 3 days of therapeutic hypothermia. Normal values were defined as 7-35 IU/L for alanine aminotransferase (ALT) and 2-70 IU/L for aspartate aminotransferase (AST).
Amplitude-Integrated EEG Monitoring
Bilateral aEEG recording commenced as soon as possible after consent was obtained and continued throughout the cooling and rewarming protocol (BRM-2, BraiNZ Instruments, Auckland, New Zealand). The infants' clinicians reviewed, and acted upon, the aEEG traces during bedside rounds and as needed per the neonatal intensive care unit clinical treatment protocol. If seizures were suspected, conventional video-EEG monitoring was initiated. Off-line aEEG analyses were performed using proprietary software (Analyze Research version 1.4, BraiNZ Instruments, Auckland, New Zealand) to facilitate objective and reproducible analyses. The mean and standard deviations for the minimum, maximum, and mean amplitudes, for the left and right aEEG traces were calculated, as well as the validated spectral edge frequency, for each 12-hour interval during the 72-hour cooling period. These variables, rather than classification of aEEG background though pattern recognition, were selected to allow quantitative, objective, and reproducible statistical analyses of continuous variables, instead of ordinal or dichotomous regression models, thereby improving overall statistical power.
Near-Infrared Spectroscopy Monitoring
Neonatal near-infrared spectroscopy sensors (Invos 5100c, Somanetics, Troy, MI) were placed over bilateral parietal regions, with 1 additional sensor over the quadriceps for systemic measurements, and recording started as soon as possible after obtaining consent. Nearinfrared spectroscopy-measured rSO 2 was collected every 5 seconds and data were extracted with proprietary software (Somanetics Corp, Troy, MI). The averages and standard deviations for the left and right cerebral and the systemic measurements rSO 2 were calculated for each 12-hour interval during the 72-hour cooling period. Since the clinical implications of near-infrared spectroscopy data are uncertain in this patient population, the results were analyzed off-line and were not available to the treating clinicians.
Developmental Follow-Up Assessments
Bayley Scales of Infant Development version 3 were recorded at 18 months. Adverse outcomes were defined as death or Bayley Scales of Infant Development cognitive and language score <85. 25 Gross motor function classification system 26 scores were also recorded at 18 months.
Statistical Analyses
To assess for differences in acute kidney injury and liver function among infants with favorable versus adverse outcomes, t tests, chisquare tests, and Fischer's exact tests were employed. The relationships between near-infrared spectroscopy and aEEG data at each 12hour interval and 18-month outcomes were assessed with independent sample t-tests for the dichotomous (favorable vs adverse) outcome. For this pilot study, the authors did not adjust for multiple comparisons; P < .05 was taken to be significant. Stata was used for all analyses (College Station, TX).
Results
Twenty-one infants were enrolled and outcomes are available for 18 (3 were lost to follow-up). Details of this cohort's acute neonatal intensive care unit course were previously reported. 21 Demographic, clinical, and follow-up data are presented in Table 1 . Five of the patients had adverse outcomes (3 deaths). Four patients had neonatal seizures, of whom 2 had adverse outcome, and 2 had good outcome. Two patients had abnormal gross motor function classification system scores (n ¼ 1 level II and n ¼ 1 level III); both met additional criteria for adverse outcomes. None of the patients had epilepsy, blindness, or severe hearing impairment at the time of follow-up.
Systemic Variables
Acute kidney injury was documented in 6 subjects, while 11 had no acute kidney injury (insufficient data were available for 1 infant). The presence of acute kidney injury did not distinguish those who went on to have favorable versus adverse outcomes (3/12 with good outcome had acute kidney injury vs 3/5 with adverse outcome; P ¼ .28). The authors lacked power to evaluate associations according to the grade of acute kidney injury. There was no association between significantly elevated liver function tests (>300% of normal AST or ALT) on day of life 1, 2, or 3 and developmental outcome (P > .9 for all comparisons).
Amplitude-Integrated EEG Variables
Several aEEG variables were predictive of outcomes. There were insufficient data to analyze aEEG from the first 12 hours of hypothermia, but aEEG data from hours 12 through 48 of cooling were associated with outcomes. Mean aEEG amplitude during hours 24-48 of cooling was higher among those with good outcomes (P ¼ .027 to .032; Figure 1a ). The aEEG lower margin was also higher during hours 12-48 for those with good outcomes (P ¼ .014 to .035; Figure 1b ). The spectral edge frequency data showed no significant relationship with outcome (P > .05 for all time points).
Near-Infrared Spectroscopy Variables
Both cerebral and systemic rSO 2 remained within the expected normal range (>70) at all times for all infants. There was no relationship between cerebral rSO 2 or and outcome (P > .05 at all time-points; Figure 2a ). Absolute values of systemic rSO 2 did not distinguish between those with favorable versus adverse outcomes. However systemic rSO 2 variability was highest during hours 48-72 of cooling among those with favorable outcomes (P ¼ .02 to .03; Figure 2b ).
Discussion
Continuous monitoring with aEEG and near-infrared spectroscopy is feasible during therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. The authors demonstrate here that objective, quantitative aEEG data recorded during the first 48 hours of hypothermia have prognostic value-higher amplitudes (less discontinuity) are associated with favorable 18-month neurodevelopmental outcomes. The authors echo their previous report that cerebral near-infrared spectroscopy data do not distinguish between neonates who go on to have good versus poor outcomes. The authors also add that decreased systemic rSO 2 variability during the third day of hypothermia may be a marker of illness and is associated with adverse 18-month outcomes. However, in this pilot study, neither liver nor kidney dysfunction was associated with outcomes.
Others have reported that normalizing aEEG patterns within the first 48 hours of life are associated with favorable outcomes among infants with who receive therapeutic hypothermia. 12 The authors' quantitative aEEG results confirm this observation and validate aEEG as a useful prognostic monitoring device for this patient population. Of note, the authors' previous work suggested that aEEG recorded during and after rewarming did not distinguish those with adverse short-term neurologic outcomes, 21 and the present work confirms that aEEG data from the third day of cooling do not add prognostic value.
The presence of acute kidney injury was reported to be a predictor of abnormal brain MRI at 7-10 days of life in asphyxiated newborns (odds ratio 3.2, 95% confidence interval 1.3-8.2), 22 however, there was no correlation between the stage of acute kidney injury and the degree of brain MRI abnormalities. Short-term markers of abnormal neurologic outcome can be imprecise predictors of long-term neurodevelopment. The authors did not uncover the same relationship between acute kidney injury and 18-month outcomes, possibly because of the small sample size (in the authors' study, 25% of those with favorable outcome had acute kidney injury, versus 60% with adverse outcome, but P ¼ .28). Hepatic dysfunction was not associated with outcomes in the authors' cohort, either. However, the authors speculate that a lack of systemic rSO 2 variability is marker of systemic illness severity and demonstrate that this variable-measured on the third day of therapeutic hypothermia-is predictive of both short-term 21 and 18month neurologic abnormalities. Neonates with birth asphyxia commonly have substantial multiorgan dysfunction. Hepatic and renal dysfunction could simply serve as markers of severe hypoxic ischemic encephalopathy rather than specifically contributing to adverse outcomes. Conversely, severe systemic illness may predispose to complications, such as fluid and electrolyte abnormalities or coagulopathy, that compound risk for adverse outcome. The prognostic utility of near-infrared spectroscopy data has been evaluated previously for neonates with hypoxic ischemic encephalopathy. Prior to the era of therapeutic hypothermia, cerebral rSO 2 was reported to distinguish 10 infants with adverse outcome (all but 1 of whom died after redirection of care) from 8 with favorable 18-month neurodevelopment. 16 When the same research team repeated a similar study with 39 infants treated with therapeutic hypothermia, they reported similar results. rSO 2 values were significantly higher among the 13 infants with adverse outcome (12 of whom died in the neonatal period) than the 26 with good outcomes from hour 24 of life onward. The authors also commented that aEEG appeared more robust than near-infrared spectroscopy as a predictive tool. 17 Another small study reported similar findings (n ¼ 12). 27 Figure 1 . The average aEEG amplitude was significantly higher during hours 24-48 (panel A; *P ¼ .027 to .032), as was the average lower margin of the aEEG during hours 12-48 of cooling (panel B; *P ¼ .014 to .035), among those with favorable versus adverse 18-month outcomes. There were insufficient aEEG data for the first 12 hours for infants with adverse outcomes. The boxplots present median and 25th and 75th percentiles, while the whiskers extend to 1.5Â interquartile range. Circles represent outliers. The prior studies' methods were slightly different from ours, which might explain the divergent conclusions. First, the previously published studies utilized pediatric near-infrared spectroscopy sensors which were placed over the frontal region, while the authors employed the Food and Drug Administration-approved neonatal sensors and applied them over the parietal regions (overlying the cerebrovascular watershed zones). The different sensors are reported to provide somewhat divergent data. 28 Second, the authors speculate that the culture surrounding withdrawal of intensive care for critically ill neonates may be differ and note that in the Dutch studies, the majority of those with adverse outcomes died after redirection of the goals of care during the neonatal period. 16, 17 Third, the other studies utilized Griffiths' Mental Development Scale, while the authors' long-term outcomes were defined by Bayley Scales of Infant Development results.
Strengths of the study include the use of near-infrared spectroscopy data recorded with neonatal sensors placed over the cerebrovascular watershed zone. This type of sensor is most likely to be employed both in American clinical practice and in future clinical trials. Unique in the extant literature is the assessment of systemic near-infrared spectroscopy data for this patient population. In addition, the authors employed objective aEEG data analysis. Objective analysis of aEEG should be more reproducible between institutions than subjective analyses of background patterns and ought, therefore, to be of value for future multicenter studies.
The primary limitation of this work is the small sample size, a problem that has affected much of the comparable literature. 17, 27 Because of the limited sample size, the authors are unable to assess for effects of medication (eg, phenobarbital) or other factors that could, in theory, affect aEEG and/or near-infrared spectroscopy data. In addition, there were limited aEEG and nearinfrared spectroscopy data for hours 0-12 of hypothermia, due to delays in obtaining consent and beginning neuromonitoring, so the authors are unable to comment on the utility of the aEEG and near-infrared spectroscopy data during the first hours of therapeutic hypothermia. However, others have shown that aEEG during these first hours of life lack predictive value for infants treated with therapeutic hypothermia. [11] [12] [13] All of the authors' data were analyzed off-line; additional evidence is required before such data can be applied in real-time in clinical practice.
Conclusion
Improving methods for early identification of hypothermiatreated infants with hypoxic ischemic encephalopathy who remain at elevated risk for adverse outcomes is a priority. Such methods might be suitable for selection of subjects for future trials which evaluate adjuvant interventions. Although near-infrared spectroscopy is increasingly used to monitor cerebral perfusion and oxygen metabolism in the neonatal intensive care unit, its role for neonates with hypoxic ischemic encephalopathy remains uncertain. However, the authors confirm that some objective aEEG variables during the first 2 days of cooling distinguish those who go on to experience good versus adverse outcomes after hypoxic ischemic encephalopathy. Additional study of systemic variables, such as markers of renal or hepatic dysfunction, is warranted. Use of near-infrared spectroscopy data as a biomarker of systemic illness may be of interest for future studies.
